Volunteers are needed to test the effectiveness of an investigational drug that may partially improve muscle strength in patients with this disease, said Dr. Yadollah Harati, professor of neurology and lead investigator on the clinical trial.

Myasthenia Gravis is a chronic autoimmune neuromuscular disease caused by a defect in the transmission of nerve impulses to muscles. It occurs when normal communication between the nerve and muscle is interrupted at the neuromuscular junction, which is the place where nerve cells connect with the muscles they control.

Men and women between the ages of 18 and 80 who are diagnosed with generalized Myasthenia Gravis are eligible to sign up for the study. They must be experiencing limb muscle weakness and fatigue but have stable symptoms.